← Back to Search

Other

Cross Linking for Treatment of Corneal Infection

N/A
Waitlist Available
Led By Francis W Price, MD
Research Sponsored by Price Vision Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* diagnosis of infectious keratitis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This study is comparing 45 minute and 30 minute treatment durations with the UVX corneal cross linking system to treat corneal infections.

Eligible Conditions
  • Corneal Infection

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: 30 minute light durationActive Control2 Interventions
30 minute treatment with UVX light
Group II: 45 minute light durationActive Control1 Intervention
45 minute treatment with UVX light

Find a Location

Who is running the clinical trial?

Price Vision GroupLead Sponsor
11 Previous Clinical Trials
1,652 Total Patients Enrolled
Cornea Research Foundation of AmericaOTHER
7 Previous Clinical Trials
2,989 Total Patients Enrolled
Francis W Price, MDPrincipal InvestigatorPrice Vision Group
2 Previous Clinical Trials
774 Total Patients Enrolled
~2 spots leftby Dec 2025